These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34877924)

  • 1. Systematic review and meta-analysis of the predictive power of
    Bai Y; Ma X; Zhang YH
    J Chemother; 2022 Nov; 34(7):472-482. PubMed ID: 34877924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer.
    Lan G; Lin L; Chen X; Chen L; Chen X
    Med Sci Monit; 2017 Nov; 23():5683-5689. PubMed ID: 29186089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
    Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
    J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
    Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
    Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study.
    Takeda Y; Naka G; Katsuya Y; Kobayashi K; Suzuki M; Hashimoto M; Hirano S; Uemura Y
    BMC Cancer; 2023 Aug; 23(1):800. PubMed ID: 37633908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
    Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
    Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study.
    Vázquez C; Orlova M; Verzura MA; Minatta JN; Scibona P; Jáuregui EG; Díaz de Arce H; Pallotta MG; Belloso WH
    J Chemother; 2019 Apr; 31(2):95-104. PubMed ID: 30739598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
    Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
    Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.
    Zhu N; Gong Y; He J; Xia J; Chen X
    Yonsei Med J; 2013 Nov; 54(6):1384-93. PubMed ID: 24142642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
    Sakai K; Tsuboi M; Kenmotsu H; Yamanaka T; Takahashi T; Goto K; Daga H; Ohira T; Ueno T; Aoki T; Nakagawa K; Yamazaki K; Hosomi Y; Kawaguchi K; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Okabe K; Yamamoto N; Nishio K
    Cancer Sci; 2021 Jan; 112(1):388-396. PubMed ID: 33185928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
    Fukuda S; Oguri T; Kunii E; Sone K; Uemura T; Takakuwa O; Maeno K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
    Lung Cancer; 2016 Dec; 102():15-20. PubMed ID: 27987582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
    Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.